Tweet
Health Policy. 2017 Sep 21. pii: S0168-8510(17)30223-3. doi: 10.1016/j.healthpol.2017.08.010. [Epub ahead of print]
Optimising the introduction of multiple childhood vaccines in Japan: A model proposing the introduction sequence achieving the highest health gains.
Standaert B1, Schecroun N2, Ethgen O3, Topachevskyi O4, Morioka Y5, Van Vlaenderen I6.
Author information
Abstract
BACKGROUND:
Many countries struggle with the prioritisation of introducing new vaccines because of budget limitations and lack of focus on public health goals. A model has been developed that defines how specific health goals can be optimised through immunisation within vaccination budget constraints.
METHODS:
Japan, as a country example, could introduce 4 new pediatric vaccines targeting influenza, rotavirus, pneumococcal disease and mumps with known burden of disease, vaccine efficacies and maximum achievable coverages. Operating under budget constraints, the Portfolio-model for the Management of Vaccines (PMV) identifies the optimal vaccine ranking and combination for achieving the maximum QALY gain over a period of 10 calendar years in children <5 years old. This vaccine strategy, of interest and helpful for a healthcare decision maker, is compared with an unranked vaccine selection process.
RESULTS:
Results indicate that the maximum QALY gain with a fixed annual vaccination budget of 500 billion Japanese Yen over a 10-year period is 72,288 QALYs using the optimal sequence of vaccine introduction (mumps [1st], followed by influenza [2nd], rotavirus [3rd], and pneumococcal [4th]). With exactly the same budget but without vaccine ranking, the total QALY gain can be 20% lower.
CONCLUSION:
The PMV model could be a helpful tool for decision makers in those environments with limited budget where vaccines have to be selected for trying to optimise specific health goals.
Copyright ? 2017 GlaxoSmithKline Biologicals SA. Published by Elsevier B.V. All rights reserved.
KEYWORDS:
Budget; Infectious diseases; Japan; Objective function; Optimisation model; Portfolio; Vaccine
PMID: 29079394 DOI: 10.1016/j.healthpol.2017.08.010
Free full text
Optimising the introduction of multiple childhood vaccines in Japan: A model proposing the introduction sequence achieving the highest health gains.
Standaert B1, Schecroun N2, Ethgen O3, Topachevskyi O4, Morioka Y5, Van Vlaenderen I6.
Author information
Abstract
BACKGROUND:
Many countries struggle with the prioritisation of introducing new vaccines because of budget limitations and lack of focus on public health goals. A model has been developed that defines how specific health goals can be optimised through immunisation within vaccination budget constraints.
METHODS:
Japan, as a country example, could introduce 4 new pediatric vaccines targeting influenza, rotavirus, pneumococcal disease and mumps with known burden of disease, vaccine efficacies and maximum achievable coverages. Operating under budget constraints, the Portfolio-model for the Management of Vaccines (PMV) identifies the optimal vaccine ranking and combination for achieving the maximum QALY gain over a period of 10 calendar years in children <5 years old. This vaccine strategy, of interest and helpful for a healthcare decision maker, is compared with an unranked vaccine selection process.
RESULTS:
Results indicate that the maximum QALY gain with a fixed annual vaccination budget of 500 billion Japanese Yen over a 10-year period is 72,288 QALYs using the optimal sequence of vaccine introduction (mumps [1st], followed by influenza [2nd], rotavirus [3rd], and pneumococcal [4th]). With exactly the same budget but without vaccine ranking, the total QALY gain can be 20% lower.
CONCLUSION:
The PMV model could be a helpful tool for decision makers in those environments with limited budget where vaccines have to be selected for trying to optimise specific health goals.
Copyright ? 2017 GlaxoSmithKline Biologicals SA. Published by Elsevier B.V. All rights reserved.
KEYWORDS:
Budget; Infectious diseases; Japan; Objective function; Optimisation model; Portfolio; Vaccine
PMID: 29079394 DOI: 10.1016/j.healthpol.2017.08.010
Free full text